{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:14:05Z","timestamp":1776928445435,"version":"3.51.2"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013015","name":"Cedars-Sinai Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013015","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, with a 5 year survival rate of approximately 13%. Survival is extended for the few patients who undergo surgical resection with curative intent, whereas most patients succumb to distant disease recurrence. Neoadjuvant platinum-based chemotherapy has emerged as a promising strategy to improve resectability rates and survival outcomes for PDAC patients. However, treatment-related toxicities, unpredictable clinical responses, and associated risk of tumor progression during neoadjuvant therapy may delay or preclude curative resection.As a result, predictive biomarkers are needed to identify patients most likely to benefit from neoadjuvant platinum-based chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Alterations in the homologous recombination (HR) DNA repair pathway are reported in 3.0\u201319.5% of PDAC patients. These types of alterations can sensitize tumors to platinum-based chemotherapy in PDAC as well as other cancers including ovarian, colorectal, and prostate cancers. Retrospective and prospective studies in locally advanced\/metastatic PDAC demonstrate higher response rates and longer survival outcomes among HR-deficient (HRD) patients receiving platinum-based chemotherapy. A growing body of evidence in the neoadjuvant setting suggests a potential benefit for HRD-PDAC patients in terms of enhanced tumor downstaging, higher resectability, and improved survival outcomes compared with HR-proficient patients. However, prospective ad hoc studies are still warranted to confirm these findings<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Homologous recombination deficiency represents a promising biomarker to guide patient selection for neoadjuvant platinum-based chemotherapy in PDAC. Incorporation of HR deficiency-testing into neoadjuvant treatment schemes will enable a more personalized therapeutic approach, supporting the implementation of precision oncology for early-stage PDAC patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-19056-0","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T19:37:23Z","timestamp":1769888243000},"page":"3583-3592","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Implications of Homologous Recombination Deficiency for Neoadjuvant Platinum-Based Chemotherapy in Pancreatic Cancer: A Narrative Review"],"prefix":"10.1245","volume":"33","author":[{"given":"Luigi","family":"Liguori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ventin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liti","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arsen","family":"Osipov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Sabbatino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina R.","family":"Ferrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"19056_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin."},{"key":"19056_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin."},{"key":"19056_CR3","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul J-L, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379:2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","journal-title":"N Engl J Med."},{"key":"19056_CR4","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, Castan F, Lopez A, Turpin A, Ben Abdelghani M, Wei AC, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8:1571\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3829.","journal-title":"JAMA Oncol."},{"key":"19056_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","volume":"270","author":"G Gemenetzis","year":"2019","unstructured":"Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340\u20137. https:\/\/doi.org\/10.1097\/SLA.0000000000002753.","journal-title":"Ann Surg."},{"key":"19056_CR6","doi-asserted-by":"publisher","first-page":"zrad137","DOI":"10.1093\/bjsopen\/zrad137","volume":"7","author":"I Farnes","year":"2023","unstructured":"Farnes I, Kleive D, Verbeke CS, Aabakken L, Issa-Epe A, Sm\u00e5stuen MC, et al. Resection rates and intention-to-treat outcomes in borderline and locally advanced pancreatic cancer: real-world data from a population-based, prospective cohort study (NORPACT-2). BJS Open. 2023;7:zrad137. https:\/\/doi.org\/10.1093\/bjsopen\/zrad137.","journal-title":"BJS Open."},{"key":"19056_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","volume":"8","author":"P Ghaneh","year":"2023","unstructured":"Ghaneh P, Palmer D, Cicconi S, Jackson R, Halloran CM, Rawcliffe C, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:157\u201368. https:\/\/doi.org\/10.1016\/S2468-1253(22)00348-X.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"19056_CR8","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1093\/jnci\/djz073","volume":"111","author":"QP Janssen","year":"2019","unstructured":"Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, et al. Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis. J Natl Cancer Inst. 2019;111:782\u201394. https:\/\/doi.org\/10.1093\/jnci\/djz073.","journal-title":"J Natl Cancer Inst."},{"key":"19056_CR9","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jnci\/djac018","volume":"114","author":"QP Janssen","year":"2022","unstructured":"Janssen QP, van Dam JL, Doppenberg D, Prakash LR, van Eijck CHJ, Jarnagin WR, et al. FOLFIRINOX as initial treatment for localized pancreatic adenocarcinoma: a retrospective analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst. 2022;114:695\u2013703. https:\/\/doi.org\/10.1093\/jnci\/djac018.","journal-title":"J Natl Cancer Inst."},{"key":"19056_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","volume":"4","author":"JE Murphy","year":"2018","unstructured":"Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4:963\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0329.","journal-title":"JAMA Oncol."},{"key":"19056_CR11","doi-asserted-by":"publisher","first-page":"6373","DOI":"10.1245\/s10434-024-15817-5","volume":"31","author":"AV Eade","year":"2024","unstructured":"Eade AV, Friedman LR, Larrain C, Rainey A, Hernandez JM, Chawla A, et al. ALLIANCE A021806: a phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer. Ann Surg Oncol. 2024;31:6373\u20134. https:\/\/doi.org\/10.1245\/s10434-024-15817-5.","journal-title":"Ann Surg Oncol."},{"key":"19056_CR12","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1186\/s12885-023-11141-5","volume":"23","author":"JL van Dam","year":"2023","unstructured":"van Dam JL, Verkolf EMM, Dekker EN, Bonsing BA, Bratlie SO, Brosens LAA, et al. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer. 2023;23:728. https:\/\/doi.org\/10.1186\/s12885-023-11141-5.","journal-title":"BMC Cancer."},{"key":"19056_CR13","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/SLA.0000000000006610","volume":"281","author":"L Huang","year":"2025","unstructured":"Huang L, Han Q, Zhao L, Wang Z, Dai G, Shi Y. Development and validation of the predictive and prognostic ChemoResist signature in resected pancreatic ductal adenocarcinoma: multicohort study. Ann Surg. 2025;281:632\u201344. https:\/\/doi.org\/10.1097\/SLA.0000000000006610.","journal-title":"Ann Surg."},{"key":"19056_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/OP-25-00548","author":"ES Agritelley","year":"2025","unstructured":"Agritelley ES, Ramaker RC, Bao M, Bolch E, Allen PJ, Strickler JH, et al. Preparing for the inevitable: early comprehensive genomic profiling for patients with localized pancreatic ductal adenocarcinoma. JCO Oncol Pract. 2025. https:\/\/doi.org\/10.1200\/OP-25-00548.","journal-title":"JCO Oncol Pract."},{"key":"19056_CR15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang R, Zhou P-K. DNA damage repair: historical perspectives, mechanistic pathways, and clinical translation for targeted cancer therapy. Sig Transduct Target Ther. 2021;6:254. https:\/\/doi.org\/10.1038\/s41392-021-00648-7.","journal-title":"Sig Transduct Target Ther."},{"key":"19056_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","volume":"26","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Rondinelli B, D\u2019Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26:52\u201364. https:\/\/doi.org\/10.1016\/j.tcb.2015.07.009.","journal-title":"Trends Cell Biol."},{"key":"19056_CR17","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1001\/jama.2018.6228","volume":"319","author":"C Hu","year":"2018","unstructured":"Hu C, Hart SN, Polley EC, Gnanaolivu R, Shimelis H, Lee KY, et al. Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer. JAMA. 2018;319:2401\u20139. https:\/\/doi.org\/10.1001\/jama.2018.6228.","journal-title":"JAMA."},{"key":"19056_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","volume":"148","author":"RC Grant","year":"2015","unstructured":"Grant RC, Selander I, Connor AA, Selvarajah S, Borgida A, Briollais L, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015;148:556\u201364. https:\/\/doi.org\/10.1053\/j.gastro.2014.11.042.","journal-title":"Gastroenterology."},{"key":"19056_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10555-021-09983-1","volume":"40","author":"F Crowley","year":"2021","unstructured":"Crowley F, Park W, O\u2019Reilly EM. Targeting DNA damage repair pathways in pancreas cancer. Cancer Metastasis Rev. 2021;40:891\u2013908. https:\/\/doi.org\/10.1007\/s10555-021-09983-1.","journal-title":"Cancer Metastasis Rev."},{"key":"19056_CR20","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1158\/0008-5472.CAN-23-0628","volume":"83","author":"J Murai","year":"2023","unstructured":"Murai J, Pommier Y. BRCAness, homologous recombination deficiencies, and synthetic lethality. Cancer Res. 2023;83:1173\u20134. https:\/\/doi.org\/10.1158\/0008-5472.CAN-23-0628.","journal-title":"Cancer Res."},{"key":"19056_CR21","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/JU.0000000000001819","volume":"206","author":"L Fan","year":"2021","unstructured":"Fan L, Fei X, Zhu Y, Chi C, Pan J, Sha J, et al. Distinct response to platinum-based chemotherapy among patients with metastatic castration-resistant prostate cancer harboring alterations in genes involved in homologous recombination. J Urol. 2021;206:630\u20137. https:\/\/doi.org\/10.1097\/JU.0000000000001819.","journal-title":"J Urol."},{"key":"19056_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/jnci\/djab169","volume":"114","author":"R Moretto","year":"2021","unstructured":"Moretto R, Elliott A, Zhang J, Arai H, Germani MM, Conca V, et al. Homologous recombination deficiency alterations in colorectal cancer: clinical, molecular, and prognostic implications. J Natl Cancer Inst. 2021;114:271\u20139. https:\/\/doi.org\/10.1093\/jnci\/djab169.","journal-title":"J Natl Cancer Inst."},{"key":"19056_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13048-023-01129-x","volume":"16","author":"Z Feng","year":"2023","unstructured":"Feng Z, Shao D, Cai Y, Bi R, Ju X, Chen D, et al. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma. J Ovarian Res. 2023;16:53. https:\/\/doi.org\/10.1186\/s13048-023-01129-x.","journal-title":"J Ovarian Res."},{"key":"19056_CR24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2021.02.035","volume":"149","author":"F Schettini","year":"2021","unstructured":"Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, et al. Poly (ADP-ribose) polymerase inhibitors in solid tumours: systematic review and meta-analysis. Eur J Cancer. 2021;149:134\u201352. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.035.","journal-title":"Eur J Cancer."},{"key":"19056_CR25","doi-asserted-by":"publisher","first-page":"175883592210830","DOI":"10.1177\/17588359221083050","volume":"14","author":"M Emelyanova","year":"2022","unstructured":"Emelyanova M, Pudova E, Khomich D, Krasnov G, Popova A, Abramov I, et al. Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes. Ther Adv Med Oncol. 2022;14:17588359221083050. https:\/\/doi.org\/10.1177\/17588359221083050.","journal-title":"Ther Adv Med Oncol."},{"key":"19056_CR26","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1158\/1078-0432.CCR-19-0224","volume":"26","author":"JB Goldstein","year":"2020","unstructured":"Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle MM, et al. Germline DNA sequencing reveals novel mutations predictive of overall survival in a cohort of patients with pancreatic cancer. Clin Cancer Res. 2020;26:1385\u201394. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0224.","journal-title":"Clin Cancer Res."},{"key":"19056_CR27","doi-asserted-by":"publisher","first-page":"4382","DOI":"10.1002\/cncr.29664","volume":"121","author":"EE Salo-Mullen","year":"2015","unstructured":"Salo-Mullen EE, O\u2019Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, et al. Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015;121:4382\u20138. https:\/\/doi.org\/10.1002\/cncr.29664.","journal-title":"Cancer."},{"key":"19056_CR28","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.20.03238","volume":"39","author":"R Casolino","year":"2021","unstructured":"Casolino R, Paiella S, Azzolina D, Beer PA, Corbo V, Lorenzoni G, et al. Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis. JCO. 2021;39:2617\u201331. https:\/\/doi.org\/10.1200\/JCO.20.03238.","journal-title":"JCO."},{"key":"19056_CR29","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1158\/0008-5472.CAN-03-3823","volume":"64","author":"AP Klein","year":"2004","unstructured":"Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJA, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634\u20138. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3823.","journal-title":"Cancer Res."},{"key":"19056_CR30","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jamcollsurg.2017.12.021","volume":"226","author":"AB Blair","year":"2018","unstructured":"Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, et al. BRCA1\/BRCA2 germline mutation carriers and sporadic pancreatic ductal adenocarcinoma. J Am Coll Surg. 2018;226:630-7.e1. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.021.","journal-title":"J Am Coll Surg."},{"key":"19056_CR31","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ccr.2010.10.015","volume":"18","author":"F Skoulidis","year":"2010","unstructured":"Skoulidis F, Cassidy LD, Pisupati V, Jonasson JG, Bjarnason H, Eyfjord JE, et al. Germline Brca2 heterozygosity promotes Kras(G12D) -driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010;18:499\u2013509. https:\/\/doi.org\/10.1016\/j.ccr.2010.10.015.","journal-title":"Cancer Cell."},{"key":"19056_CR32","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/j.gastro.2010.12.039","volume":"140","author":"M Rowley","year":"2011","unstructured":"Rowley M, Ohashi A, Mondal G, Mills L, Yang L, Zhang L, et al. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology. 2011;140:1303\u201313. https:\/\/doi.org\/10.1053\/j.gastro.2010.12.039.","journal-title":"Gastroenterology."},{"key":"19056_CR33","doi-asserted-by":"publisher","first-page":"6513","DOI":"10.1038\/s41467-022-34081-3","volume":"13","author":"L Shaashua","year":"2022","unstructured":"Shaashua L, Ben-Shmuel A, Pevsner-Fischer M, Friedman G, Levi-Galibov O, Nandakumar S, et al. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking cluster in expression in cancer-associated fibroblasts with HSF1 signaling. Nat Commun. 2022;13:6513. https:\/\/doi.org\/10.1038\/s41467-022-34081-3.","journal-title":"Nat Commun."},{"key":"19056_CR34","doi-asserted-by":"publisher","first-page":"860767","DOI":"10.3389\/fonc.2022.860767","volume":"12","author":"B Golesworthy","year":"2022","unstructured":"Golesworthy B, Wang Y, Tanti A, Pacis A, Romero JM, Cuggia A, et al. Intra-tumoral CD8+ T-cell infiltration and PD-L1 positivity in homologous recombination-deficient pancreatic ductal adenocarcinoma. Front Oncol. 2022;12:860767. https:\/\/doi.org\/10.3389\/fonc.2022.860767.","journal-title":"Front Oncol."},{"key":"19056_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000942","volume":"5","author":"A Seeber","year":"2020","unstructured":"Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, et al. Molecular characteristics of BRCA1\/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. ESMO Open. 2020;5:e000942. https:\/\/doi.org\/10.1136\/esmoopen-2020-000942.","journal-title":"ESMO Open."},{"key":"19056_CR36","doi-asserted-by":"publisher","first-page":"217699","DOI":"10.1016\/j.canlet.2025.217699","volume":"622","author":"K Br\u00e4utigam","year":"2025","unstructured":"Br\u00e4utigam K, Skok K, Szymonski K, Rift CV, Karamitopoulou E. Tumor immune microenvironment in pancreatic ductal adenocarcinoma revisited: exploring the \u201cspace.\u201d Cancer Lett. 2025;622:217699. https:\/\/doi.org\/10.1016\/j.canlet.2025.217699.","journal-title":"Cancer Lett."},{"key":"19056_CR37","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00092","volume":"7","author":"JCF Quintanilha","year":"2023","unstructured":"Quintanilha JCF, Storandt MH, Graf RP, Li G, Keller R, Lin DI, et al. Tumor mutational burden in real-world patients with pancreatic cancer: genomic alterations and predictive value for immune checkpoint inhibitor effectiveness. JCO Precis Oncol. 2023;7:e2300092. https:\/\/doi.org\/10.1200\/PO.23.00092.","journal-title":"JCO Precis Oncol."},{"key":"19056_CR38","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, Blais EM, Brody JR, Lyons E, DeArbeloa P, Hendifar A, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol. 2020;21:508\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(20)30074-7.","journal-title":"Lancet Oncol."},{"key":"19056_CR39","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.4161\/cc.10.8.15273","volume":"10","author":"KJ Dedes","year":"2011","unstructured":"Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations. Cell Cycle. 2011;10:1192\u20139. https:\/\/doi.org\/10.4161\/cc.10.8.15273.","journal-title":"Cell Cycle."},{"key":"19056_CR40","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1126\/science.278.5340.1064","volume":"278","author":"LH Hartwell","year":"1997","unstructured":"Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science. 1997;278:1064\u20138. https:\/\/doi.org\/10.1126\/science.278.5340.1064.","journal-title":"Science."},{"key":"19056_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","volume":"5","author":"T Helleday","year":"2011","unstructured":"Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011;5:387\u201393. https:\/\/doi.org\/10.1016\/j.molonc.2011.07.001.","journal-title":"Mol Oncol."},{"key":"19056_CR42","doi-asserted-by":"publisher","first-page":"6204","DOI":"10.1158\/1078-0432.CCR-18-1472","volume":"24","author":"A Sehdev","year":"2018","unstructured":"Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, et al. Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX. Clin Cancer Res. 2018;24:6204\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1472.","journal-title":"Clin Cancer Res."},{"key":"19056_CR43","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","volume":"26","author":"W Park","year":"2020","unstructured":"Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, et al. Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection. Clin Cancer Res. 2020;26:3239\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0418.","journal-title":"Clin Cancer Res."},{"key":"19056_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg MM, Asch D, Yu S, O\u2019Dwyer PJ, Domchek SM, Nathanson KL, et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2, or PALB2 mutation. Br J Cancer. 2020;122:333\u20139. https:\/\/doi.org\/10.1038\/s41416-019-0582-7.","journal-title":"Br J Cancer."},{"key":"19056_CR45","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med."},{"key":"19056_CR46","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1200\/JCO.21.00003","volume":"39","author":"KA Reiss","year":"2021","unstructured":"Reiss KA, Mick R, O\u2019Hara MH, Teitelbaum U, Karasic TB, Schneider C, et al. Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 2021;39:2497\u2013505. https:\/\/doi.org\/10.1200\/JCO.21.00003.","journal-title":"J Clin Oncol."},{"issue":"4 Suppl","key":"19056_CR47","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.2025.43.4_suppl.715","volume":"43","author":"PJ Hosein","year":"2025","unstructured":"Hosein PJ, Rothe M, Garrett-Mayer E, Baron AD, Cannon TL, Pisick EP, et al. Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with BRCA1\/2 mutation (mut): results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. JCO. 2025;43(4 Suppl):715\u2013715. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.715.","journal-title":"JCO."},{"key":"19056_CR48","doi-asserted-by":"publisher","first-page":"216713","DOI":"10.1016\/j.canlet.2024.216713","volume":"587","author":"G Cattaneo","year":"2024","unstructured":"Cattaneo G, Ventin M, Arya S, Kontos F, Michelakos T, Sekigami Y, et al. Interplay between B7\u2013H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma. Cancer Lett. 2024;587:216713. https:\/\/doi.org\/10.1016\/j.canlet.2024.216713.","journal-title":"Cancer Lett."},{"key":"19056_CR49","doi-asserted-by":"publisher","first-page":"7295","DOI":"10.3390\/ijms21197295","volume":"21","author":"F Sabbatino","year":"2020","unstructured":"Sabbatino F, Liguori L, Polcaro G, Salvato I, Caramori G, Salzano FA, et al. Role of human leukocyte antigen system as a predictive biomarker for checkpoint-based immunotherapy in cancer patients. Int J Mol Sci. 2020;21:7295. https:\/\/doi.org\/10.3390\/ijms21197295.","journal-title":"Int J Mol Sci."},{"key":"19056_CR50","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJC van der Stegen","year":"2015","unstructured":"van der Stegen SJC, Hamieh M, Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov. 2015;14:499\u2013509. https:\/\/doi.org\/10.1038\/nrd4597.","journal-title":"Nat Rev Drug Discov."},{"key":"19056_CR51","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.3390\/ijms23063238","volume":"23","author":"J-L Huang","year":"2022","unstructured":"Huang J-L, Chang Y-T, Hong Z-Y, Lin C-S. Targeting DNA damage response and immune checkpoint for anticancer therapy. Int J Mol Sci. 2022;23:3238. https:\/\/doi.org\/10.3390\/ijms23063238.","journal-title":"Int J Mol Sci."},{"key":"19056_CR52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jjco\/hyy190","volume":"49","author":"F Motoi","year":"2019","unstructured":"Motoi F, Kosuge T, Ueno H, Yamaue H, Satoi S, Sho M, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol. 2019;49:190\u20134. https:\/\/doi.org\/10.1093\/jjco\/hyy190.","journal-title":"Jpn J Clin Oncol."},{"key":"19056_CR53","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","volume":"268","author":"J-Y Jang","year":"2018","unstructured":"Jang J-Y, Han Y, Lee H, Kim S-W, Kwon W, Lee K-H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg. 2018;268:215\u201322. https:\/\/doi.org\/10.1097\/SLA.0000000000002705.","journal-title":"Ann Surg."},{"key":"19056_CR54","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol."},{"key":"19056_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.19.00115","volume":"3","author":"MJ Pishvaian","year":"2019","unstructured":"Pishvaian MJ, Blais EM, Brody JR, Rahib L, Lyons E, De Arbeloa P, et al. Outcomes in patients with pancreatic adenocarcinoma with genetic mutations in DNA damage response pathways: results from the Know Your Tumor Program. JCO Precis Oncol. 2019;3:1\u201310. https:\/\/doi.org\/10.1200\/PO.19.00115.","journal-title":"JCO Precis Oncol."},{"key":"19056_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00271","volume":"3","author":"S Yu","year":"2019","unstructured":"Yu S, Agarwal P, Mamtani R, Symecko H, Spielman K, O\u2019Hara M, et al. Retrospective survival analysis of patients with resected pancreatic ductal adenocarcinoma and a germline BRCA or PALB2 mutation. JCO Precis Oncol. 2019;3:1\u201311. https:\/\/doi.org\/10.1200\/PO.18.00271.","journal-title":"JCO Precis Oncol."},{"key":"19056_CR57","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1245\/s10434-020-08469-8","volume":"27","author":"T Golan","year":"2020","unstructured":"Golan T, Barenboim A, Lahat G, Nachmany I, Goykhman Y, Shacham-Shmueli E, et al. Increased rate of complete pathologic response after neoadjuvant FOLFIRINOX for BRCA mutation carriers with borderline resectable pancreatic cancer. Ann Surg Oncol. 2020;27:3963\u201370. https:\/\/doi.org\/10.1245\/s10434-020-08469-8.","journal-title":"Ann Surg Oncol."},{"key":"19056_CR58","unstructured":"[Internet]. Neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (PDAC) with germline DNA damage repair (DDR) mutations: a dual-institution retrospective study. ASCO [cited 2025 July 11]. Available from: https:\/\/www.asco.org\/abstracts-presentations\/ABSTRACT456850"},{"key":"19056_CR59","unstructured":"NCCN [Internet]. Guidelines Detail [cited 2025 July 11]. Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1455"},{"key":"19056_CR60","unstructured":"[Internet]. Germline screening rates and patterns for patients with pancreatic cancer at an academic medical center. ASCO [cited 2025 July 11]. Available from: https:\/\/www.asco.org\/posters\/POSTER376256"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19056-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-19056-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-19056-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:47:51Z","timestamp":1773330471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-19056-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["19056"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-19056-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}